Membrane Proteome Analysis of Glioblastoma Cell Invasion

Journal of Neuropathology and Experimental Neurology

Volumn 74, Issue 5, 2015, Pages 425-441

  Mallawaaratchy, Duthika M ^a   Buckland, Michael E ^b,c   McDonald, Kerrie L ^d   Li, Cheryl C Y ^c   Ly, Linda ^b   Sykes, Erin K ^a   Christopherson, Richard I ^a   Kaufman, Kimberley L ^a,b,c  

^a School of Molecular Bioscience   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

CD97; Cell invasion; Epithelial mesenchymal transition; Glioblastoma; Integrin 5; Invadopodia; Membrane protein; Proteomics

Indexed keywords

ALPHA5 INTEGRIN; CD97 ANTIGEN; F ACTIN; FILAMIN; FILAMIN C; IMMUNOGLOBULIN; IMMUNOGLOBULIN SUPERFAMILY MEMBER 8; LIPOCORTIN 1; MEMBRANE PROTEIN; MEMBRANE PROTEOME; PHOSPHOLIPASE C; RAP PROTEIN; RAS PROTEIN; RAS RELATED PROTEIN RAP 1B; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VOLOCIXIMAB; LEUKOCYTE ANTIGEN;

ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CELL INVASION; CELL JUNCTION; CELL POPULATION; COMPARATIVE STUDY; CONTROLLED STUDY; FLUORESCENCE MICROSCOPY; GENE EXPRESSION; GLIOBLASTOMA; HUMAN; HUMAN CELL; MASS SPECTROMETRY; NUCLEIC ACID METABOLISM; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN LOCALIZATION; PROTEOMICS; SIGNAL TRANSDUCTION; SURVIVAL RATE; WESTERN BLOTTING; BRAIN TUMOR; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROCEDURES; PROTEIN DATABASE; STATISTICS AND NUMERICAL DATA; TANDEM MASS SPECTROMETRY; TUMOR CELL LINE; TUMOR INVASION;

ANNEXIN A1; ANTIGENS, CD; BRAIN NEOPLASMS; CELL LINE, TUMOR; DATABASES, PROTEIN; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM INVASIVENESS; PROTEOMICS; RNA, SMALL INTERFERING; TANDEM MASS SPECTROMETRY; TRANSFECTION;

EID: 84931030989     PISSN: 00223069     EISSN: 15546578     Source Type: Journal    
DOI: 10.1097/NEN.0000000000000187     Document Type: Article

References (112)

1. Ostrom QT, Gittleman H, Farah P, et al. CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. Neuro Oncol 2013;15:ii1-56
2. Iwamoto FM, Abrey LE, Beal K, et al. Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology 2009; 73:1200-6
3. Stylli SS, Kaye AH, Lock P. Invadopodia: At the cutting edge of tumour invasion. J Clin Neurosci2008;15:725-37
4. Weaver AM. Invadopodia: Specialized cell structures for cancer invasion. Clin Exp Metastasis 2006;23:97-105
5. Schoumacher M, Goldman RD, Louvard D, Vignjevic DM. Actin, microtubules, and vimentin intermediate filaments cooperate for elongation of invadopodia. J Cell Biol 2010;189:541-56
6. Chen WT. Proteolytic activity of specialized surface protrusions formed at rosette contact sites of transformed cells. J Exp Zool 1989;251: 167-85
7. Artym VV, Zhang Y, Seillier-Moiseiwitsch F, Yamada KM, Mueller SC. Dynamic interactions of cortactin and membrane type 1 matrix metalloproteinase at invadopodia: Defining the stages of invadopodia formation and function. Cancer Res 2006;66:3034-43
8. Albiges-Rizo C, Destaing O, Fourcade B, Planus E, Block MR. Actin machinery and mechanosensitivity in invadopodia, podosomes and focal adhesions. J Cell Sci 2009;122:3037-49
9. Larue L, Bellacosa A. Epithelial-mesenchymal transition in development and cancer: Role of phosphatidylinositol 3 kinase/AKT pathways. Oncogene 2005;24:7443-54
10. Moreno-Bueno G, Peinado H, Molina P, et al. The morphological and molecular features of the epithelial-to-mesenchymal transition. Nat Protoc 2009;4:1591-613
11. Thiery JP. Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol 2003;15:740-46
12. Yilmaz M, Christofori G. EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev 2009;28:15-33
13. Cortesio CL, Chan KT, Perrin BJ, et al. Calpain 2 and PTP1B function in a novel pathway with Src to regulate invadopodia dynamics and breast cancer cell invasion. J Cell Biol 2008;180:957-71
14. Formolo CA, Williams R, Gordish-Dressman H, MacDonald TJ, Lee NH, Hathout Y. Secretome signature of invasive glioblastoma multiforme. J Proteome Res 2011;10:3149-59
15. Helbig AO, Heck AJ, Slijper M. Exploring the membrane proteomeV challenges and analytical strategies. J Proteomics 2010;73:868-78
16. Alpert AJ. Electrostatic repulsion hydrophilic interaction chromatography for isocratic separation of charged solutes and selective isolation of phosphopeptides. Anal Chem 2008;80:62-76
17. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods 2012;9:671-75
18. Murphy DA, Courtneidge SA. The 'ins' and 'outs' of podosomes, and invadopodia: Characteristics, formation and function. Nat Rev Mol Cell Biol 2011;12:413-26
19. Wu YM, Liu CH, Hu RH, et al. Mucin glycosylating enzyme GALNT2 regulates the malignant character of hepatocellular carcinoma by modifying the EGF receptor. Cancer Res 2011;71:7270-79
20. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009;4:44-57
21. Keshava Prasad TS, Goel R, Kandasamy K, et al. Human Protein Reference DatabaseV2009 update. Nucleic Acids Res 2009;37:D767-72
22. National Cancer Institute. REMBRANDT Web site. Available at: http://rembrandt. nci. nih. gov. Accessed January 20, 2015
23. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455:1061-68
24. TCGA Research Network. The Cancer Genome Atlas Web site. Available at: http://cancergenome. nih. gov/. Accessed August 22, 2014
25. Shinojima N, Tada K, Shiraishi S, et al. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res 2003;63:6962-70
26. Wang S, Li E, Gao Y, et al. Study on invadopodia formation for lung carcinoma invasion with a microfluidic 3D culture device. PLoS One 2013;8:e56448
27. Mader CC, Oser M, Magalhaes MA, et al. An EGFR-Src-Arg-cortactin pathway mediates functional maturation of invadopodia and breast cancer cell invasion. Cancer Res 2011;71:1730-41
28. Lu Z, Jiang G, Blume-Jensen P, Hunter T. Epidermal growth factorY induced tumor cell invasion and metastasis initiated by dephosphorylation and downregulation of focal adhesion kinase. Mol Cell Biol 2001; 21:4016-31
29. Hayes KE, Walk EL, Ammer AG, Kelley LC, Martin KH, Weed SA. Ableson kinases negatively regulate invadopodia function and invasion in head and neck squamous cell carcinoma by inhibiting an HB-EGF autocrine loop. Oncogene 2013;32:4766-77
30. Ramis G, Thomas-Moyaè, Fernández de Mattos S, Rodŕguez J, Villalonga P. EGFR inhibition in glioma cells modulates Rho signaling to inhibit cell motility and invasion and cooperates with temozolomide to reduce cell growth. PLoS One 2012;7:e38770
31. Fortin Ensign SP, Mathews IT, Symons MH, Berens ME, Tran NL. Implications of Rho GTPase signaling in glioma cell invasion and tumor progression. Front Oncol 2013;3:241
32. Kwiatkowska A, Didier S, Fortin S, et al. The small GTPase RhoG mediates glioblastoma cell invasion. Mol Cancer 2012;11:65
33. Katoh H, Hiramoto K, Negishi M. Activation of Rac1 by RhoG regulates cell migration. J Cell Sci 2006;119:56-65
34. Gauthier-Rouvière C, Vignal E, Mériane M, Roux P, Montcourier P, Fort P. RhoG GTPase controls a pathway that independently activates Rac1 and Cdc42Hs. Mol Biol Cell 1998;9:1379-94
35. Chuang YY, Tran NL, Rusk N, Nakada M, Berens ME, Symons M. Role of synaptojanin 2 in glioma cell migration and invasion. Cancer Res 2004;64:8271-75
36. Karpel-Massler G, Westhoff MA, Zhou S, et al. Combined inhibition of HER1/EGFR and RAC1 results in a synergistic antiproliferative effect on established and primary cultured human glioblastoma cells. Mol Cancer Ther 2013;12:1783-95
37. Hayes MJ, Rescher U, Gerke V, Moss SE. Annexin-actin interactions. Traffic 2004;5:571-76
38. de Graauw M, van Miltenburg MH, Schmidt MK, et al. Annexin A1 regulates TGF-beta signaling and promotes metastasis formation of basal-like breast cancer cells. Proc Natl Acad Sci U S A 2010;107:6340-45
39. Yang Y, Liu Y, Yao X, et al. Annexin 1 released by necrotic human glioblastoma cells stimulates tumor cell growth through the formyl peptide receptor 1. Am J Pathol 2011;179:1504-12
40. Babbin BA, Lee WY, Parkos CA, et al. Annexin I regulates SKCO-15 cell invasion by signaling through formyl peptide receptors. J Biol Chem 2006;281:19588-99
41. Swa HL, Shaik AA, Lim LH, Gunaratne J. Mass spectrometry based quantitative proteomics and integrative network analysis accentuates modulating roles of annexin-1 in mammary tumorigenesis. Proteomics 2015;15:408-18
42. Kuwano M, Uchiumi T, Hayakawa H, et al. The basic and clinical implications of ABC transporters, Y-boxYbinding protein-1 (YB-1) and angiogenesis-related factors in human malignancies. Cancer Sci 2003; 94:9-14
43. Fotovati A, Abu-Ali S, Wang PS, et al. YB-1 bridges neural stem cells and brain tumorYinitiating cells via its roles in differentiation and cell growth. Cancer Res 2011;71:5569-78
44. Gao Y, Fotovati A, Lee C, et al. Inhibition of Y-box binding protein-1 slows the growth of glioblastoma multiforme and sensitizes to temozolomide independent O6-methylguanine-DNA methyltransferase. Mol Cancer Ther 2009;8:3276-84
45. Lasham A, Lindridge E, Rudert F, Onrust R, Watson J. Regulation of the human fas promoter by YB-1, Puralpha and AP-1 transcription factors. Gene 2000;252:1-13
46. Kleber S, Sancho-Martinez I, Wiestler B, et al. Yes and PI3K bind CD95 to signal invasion of glioblastoma. Cancer Cell 2008;13:235-48
47. Safaee M, Clark AJ, Oh MC, et al. Overexpression of CD97 confers an invasive phenotype in glioblastoma cells and is associated with decreased survival of glioblastoma patients. PLoS One 2013;8:e62765
48. Liu JK, Lubelski D, Schonberg DL, et al. Phage display discovery of novel molecular targets in glioblastoma-initiating cells. Cell Death Differ 2014;21:1325-39
49. Kolesnikova TV, Kazarov AR, Lemieux ME, et al. Glioblastoma inhibition by cell surface immunoglobulin protein EWI-2, in vitro and in vivo. Neoplasia 2009;11:77-86
50. Schröder HM, Hoffmann SC, Hecker M, Korff T, Ludwig T. The tetraspanin network modulates MT1-MMP cell surface trafficking. Int J Biochem Cell Biol 2013;45:1133-44
51. Han X, Zhang W, Yang X, et al. The role of Src family kinases in growth and migration of glioma stem cells. Int J Oncol 2014;45:302-10
52. Yadav V, Denning MF. Fyn is induced by Ras/PI3K/Akt signaling and is required for enhanced invasion/migration. Mol Carcinog 2011;50: 346-52
53. Saito YD, Jensen AR, Salgi R, Posadas EM. Fyn: A novel molecular target in cancer. Cancer 2010;116:1629-37
54. Kostic A, Sheetz MP. Fibronectin rigidity response through Fyn and p130Cas recruitment to the leading edge. Mol Biol Cell 2006;17:2684-95
55. Evdokimova V, Tognon C, Ng T, et al. Translational activation of snail1 and other developmentally regulated transcription factors by YB-1 promotes an epithelial-mesenchymal transition. Cancer Cell 2009;15: 402-15
56. Shiota M, Izumi H, Onitsuka T, et al. Twist promotes tumor cell growth through YB-1 expression. Cancer Res 2008;68:98-105
57. Yang J, Mani SA, Donaher JL, et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004;117: 927-39
58. Mikheeva SA, Mikheev AM, Petit A, et al. TWIST1 promotes invasion through mesenchymal change in human glioblastoma. Mol Cancer 2010;9:194
59. Cheung HC, Baggerly KA, Tsavachidis S, et al. Global analysis of aberrant pre-mRNA splicing in glioblastoma using exon expression arrays. BMC Genomics 2008;9:216
60. Zuo JH, Zhu W, Li MY, et al. Activation of EGFR promotes squamous carcinoma SCC10A cell migration and invasion via inducing EMT-like phenotype change and MMP-9Ymediated degradation of E-cadherin. J Cell Biochem 2011;112:2508-17
61. Hagiwara S, Murakumo Y, Sato T, et al. Up-regulation of CD109 expression is associated with carcinogenesis of the squamous epithelium of the oral cavity. Cancer Sci 2008;99:1916-23
62. Hagikura M, Murakumo Y, Hasegawa M, et al. Correlation of pathological grade and tumor stage of urothelial carcinomas with CD109 expression. Pathol Int 2010;60:735-43
63. Bizet AA, Liu K, Tran-Khanh N, et al. The TGF-A co-receptor, CD109, promotes internalization and degradation of TGF-A receptors. Biochim Biophys Acta 2011;1813:742-53
64. Bizet AA, Tran-Khanh N, Saksena A, Liu K, Buschmann MD, Philip A. CD109-mediated degradation of TGF-A receptors and inhibition of TGF-A responses involve regulation of SMAD7 and Smurf2 localization and function. J Cell Biochem 2012;113:238-46
65. Emori M, Tsukahara T, Murase M, et al. High expression of CD109 antigen regulates the phenotype of cancer stem-like cells/cancerinitiating cells in the novel epithelioid sarcoma cell line ESX and is related to poor prognosis of soft tissue sarcoma. PLoS One 2013;8: e84187
66. Bizet A. Mechanisms of Action of CD109, A Novel TGF-Beta Co-receptor [doctor of philosophy dissertation]. Montreal, Canada: McGill University, 2011
67. Mii S, Murakumo Y, Asai N, Asai M, Takahashi M. Deficiency of CD109, a negative regulator of TGF-A signaling, leads epidermal hyperplasia and appendage abnormalities in mice. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research. Chicago, IL: American Association for Cancer Research, 2012. Abstract 4250
68. Downward J. Targeting RAS signaling pathways in cancer therapy. Nat Rev Cancer 2003;3:11-22
69. Self AJ, Caron E, Paterson HF, Hall A. Analysis of R-Ras signaling pathways. J Cell Sci 2001;114:1357-66
70. Ada-Nguema AS, Xenias H, Hofman JM, Wiggins CH, Sheetz MP, Keely PJ. The small GTPase R-Ras regulates organization of actin and drives membrane protrusions through the activity of PLCepsilon. J Cell Sci 2005;119:1307-19
71. Hansen M, Prior IA, Hughes PE, et al. C-terminal sequences in R-Ras are involved in integrin regulation and in plasma membrane microdomain distribution. Biochem Biophys Res Commun 2003;311:829-38
72. Wozniak MA, Kwong L, Chodniewicz D, Klemke RL, Keely PJ. R-Ras controls membrane protrusion and cell migration through the spatial regulation of Rac and Rho. Mol Biol Cell 2005;16:84-96
73. Ridley AJ, Schwartz MA, Burridge K, et al. Cell migration: Integrating signals from front to back. Science 2003;302:1704-9
74. Malchinkhuu E, Sato K, Maehama T, et al. Role of Rap1B and tumor suppressor PTEN in the negative regulation of lysophosphatidic acidYinduced migration by isoproterenol in glioma cells. Mol Biol Cell 2009;20:5156-65
75. Ohba Y, Mochizuki N, Matsuo K, et al. Rap2 as a slowly responding molecular switch in the Rap1 signaling cascade. Mol Cell Biol 2000;20: 6074-83
76. Di JH, Qu DB, Lu Z, et al. Rap2B promotes migration and invasion of human suprarenal epithelioma. Tumour Biol 2014;35:9387-94
77. Bray IM, Dowling P, Bryan KR, et al. Proteomic analysis identifies RAB1A as a novel marker of invasion in neuroblastoma. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research. Chicago, IL: American Association for Cancer Research, 2012. Abstract 4152
78. Callow MG, Zozulya S, Gishizky ML, Jallal B, Smeal T. PAK4 mediates morphological changes through the regulation of GEF-H1. J Cell Sci 2005;118:1861-72
79. Gurski LA, Knowles LM, Basse PH, Maranchie JK, Watkins SC, Pilch J. Relocation of CLIC1 promotes tumor cell invasion and colonization of fibrin. Mol Cancer Res 2015;13:273-80
80. Knowles LM, Malik G, Hood BL, Conrads TP, Pilch J. CLT1 targets angiogenic endothelium through CLIC1 and fibronectin. Angiogenesis 2012;15:115-29
81. Setti M, Savalli N, Osti D, et al. Functional role of CLIC1 ion channel in glioblastoma-derived stem/progenitor cells. J Natl Cancer Inst 2013; 105:1644-55
82. Wang L, He S, Tu Y, et al. Elevated expression of chloride intracellular channel 1 is correlated with poor prognosis in human gliomas. J Exp Clin Cancer Res 2012;31:44
83. Chen CD, Wang CS, Huang YH, et al. Overexpression of CLIC1 in human gastric carcinoma and its clinicopathological significance. Proteomics 2007;7:155-67
84. Zheng DL, Huang QL, Zhou F, Huang QJ, Lin JY, Lin X. PA28A regulates cell invasion of gastric cancer via modulating the expression of chloride intracellular channel 1. J Cell Biochem 2012;113:1537-46
85. Yamaguchi H, Lorenz M, Kempiak S, et al. Molecular mechanisms of invadopodium formation: The role of the N-WASPYArp2/3 complex pathway and cofilin. J Cell Biol 2005;168:441-52
86. Smith-Pearson PS, Greuber EK, Yogalingam G, Pendergast AM. Abl kinases are required for invadopodia formation and chemokine-induced invasion. J Biol Chem 2010;285:40201-11
87. Oser M, Dovas A, Cox D, Condeelis J. Nck1 and Grb2 localization patterns can distinguish invadopodia from podosomes. Eur J Cell Biol 2011;90:181-88
88. Hossain S, Dubielecka PM, Sikorski AF, Birge RB, Kotula L. Crk and ABI1: Binary molecular switches that regulate abl tyrosine kinase and signaling to the cytoskeleton. Genes Cancer 2012;3:402-13
89. Wang T, Ward Y, Tian L, et al. CD97, an adhesion receptor on inflammatory cells, stimulates angiogenesis through binding integrin counterreceptors on endothelial cells. Blood 2005;105:2836-44
90. Lackner S, Schwendinger-Schreck J, Jülich D, Holley SA. Segmental assembly of fibronectin matrix requires rap1b and integrin >5. Dev Dyn 2013;242:122-31
91. Zhang Z, Vuori K, Wang HG, Reed JC, Ruoslahti E. Integrin activation by R-ras. Cell 1996;85:61-69
92. Nam EH, Lee Y, Park YK, Lee JW, Kim S. ZEB2 upregulates integrin >5 expression through cooperation with Sp1 to induce invasion during epithelial-mesenchymal transition of human cancer cells. Carcinogenesis 2012;33:563-71
93. Kita D, Takino T, Nakada M, Takahashi T, Yamashita J, Sato H. Expression of dominant-negative form of Ets-1 suppresses fibronectin-stimulated cell adhesion and migration through down-regulation of integrin alpha5 expression in U251 glioma cell line. Cancer Res 2001;61:7985-91
94. Schaffner F, Ray A, Dontenwill M. Integrin >5A1, the fibronectin receptor, as a pertinent therapeutic target in solid tumors. Cancers 2013;5: 27-47
95. Martinkova E, Maglott A, Leger DY, et al. Alpha5beta1 integrin antagonists reduce chemotherapy-induced premature senescence and facilitate apoptosis in human glioblastoma cells. Int J Cancer 2010;127: 1240-48
96. Janouskova H, Maglott A, Leger DY, et al. Integrin >5A1 plays a critical role in resistance to temozolomide by interfering with the p53 pathway in high-grade glioma. Cancer Res 2012;72:3463-70
97. Toquet C, Colson A, Jarry A, et al. ADAM15 to >5A1 integrin switch in colon carcinoma cells: A late event in cancer progression associated with tumor dedifferentiation and poor prognosis. Int J Cancer 2012;130: 278-87
98. Frisch SM, Ruoslahti E. Integrins and anoikis. Curr Opin Cell Biol 1997;9:701-6
99. Qian F, Zhang ZC, Wu XF, Li YP, Xu Q. Interaction between integrin alpha(5) and fibronectin is required for metastasis of B16F10 melanoma cells. Biochem Biophys Res Commun 2005;333:1269-75
100. Mierke CT, Frey B, Fellner M, Herrmann M, Fabry B. Integrin >5A1 facilitates cancer cell invasion through enhanced contractile forces. J Cell Sci 2010;124:369-83
101. Mueller SC, Ghersi G, Akiyama SK, et al. A novel protease-docking function of integrin at invadopodia. J Biol Chem 1999;274:24947-52
102. Paz H, Pathak N, Yang J. Invading one step at a time: The role of invadopodia in tumor metastasis. Oncogene 2014;33:4193-202
103. Eisele G, Wick A, Eisele AC, et al. Cilengitide treatment of newly diagnosed glioblastoma patients does not alter patterns of progression. J Neurooncol 2014;117:141-45
104. Stupp R, Hegi ME, Gorlia T, et al. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): A multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2014; 15:1100-8
105. Desgrosellier JS, Cheresh DA. Integrins in cancer: Biological implications and therapeutic opportunities. Nat Rev Cancer 2010;10:9-22
106. Besse B, Tsao LC, Chao DT, et al. Phase Ib safety and pharmacokinetic study of volociximab, an antiY>5A1 integrin antibody, in combination with carboplatin and paclitaxel in advanced nonYsmall-cell lung cancer. Ann Oncol 2013;24:90-96
107. Bhaskar V, Fox M, Breinberg D, et al. Volociximab, a chimeric integrin alpha5beta1 antibody, inhibits the growth of VX2 tumors in rabbits. Invest New Drugs 2008;26:7-12
108. Bhaskar V, Zhang D, Fox M, et al. A function blocking antiYmouse integrin alpha5beta1 antibody inhibits angiogenesis and impedes tumor growth in vivo. J Transl Med 2007;5:61
109. Ramakrishnan V, Bhaskar V, Law DA, et al. Preclinical evaluation of an antiYalpha5beta1 integrin antibody as a novel anti-angiogenic agent. J Exp Ther Oncol 2006;5:273-86
110. Miura FK, Alves MJ, Rocha MC, da Silva R, Oba-Shinjo SM, Marie SK. Xenograft transplantation of human malignant astrocytoma cells into immunodeficient rats: An experimental model of glioblastoma. Clinics (Sao Paulo) 2010;65:305-9
111. Nakahata AM, Suzuki DE, Rodini CO, Pereira MC, Janjoppi L, Okamoto OK. Human glioblastoma cells display mesenchymal stem cell features and form intracranial tumors in immunocompetent rats. J Stem Cells 2010;5:103-11
112. Kim JK, Jin X, Sohn YW, et al. Tumoral RANKL activates astrocytes that promote glioma cell invasion through cytokine signaling. Cancer Lett 2014;353:194-200